Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

superDimension Ltd.

This article was originally published in Start Up

Executive Summary

superDimension describes its interventional pulmonology device as a"global positioning system" for the lungs. Based on electromagnetic localization technology, superDimension combines a novel, steerable catheter that can maneuver in the tiny vessels at the lungs' periphery, with image-processing and navigation technologies that allow pulmonologists to visualize in real time the path of the catheter as it moves through the lungs.

You may also be interested in...



Device CEOs Who Find The Funding

The financial world may be in crisis, but top-tier medical device companies can still raise capital. But at what price? Four medical device execs answer those questions and many more.

The Golden Age in Cancer Medtech Investing

Short of investing in the kinds of products that must demonstrate five-year survival rates, the field of cancer offers many near term investment opportunities, and large markets to support them. As noted in US Disease Incidence and Prevalence, a report recently published by the Medtech Insight division of FDC-Windhover, like many diseases, the incidence of cancer increases with age. More than 10.8 million people in the US have a history of cancer; and in 2008, at least 1.4 million more people will be diagnosed. According to the Medtech Insight report, breast cancer has the highest prevalence rate, followed by prostate and colorectal cancers.

Lung Cancer: An Up and Coming Device Market

Lung cancer is the number one cause of deaths from cancer, in large part because it generally isn't detected until very late stages. At that point, survival rates are low and the only option is radical lung surgery. But now imaging technologies can detect smaller cancers, sooner, and in the wake of the publication of the Early Lung Cancer Action Project, the medical device industry is preparing for a paradigm shift. Start-ups are now developing technologies to remove the barriers in diagnosis and access that hinder therapeutic intervention.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037349

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel